Sichuan Cunde Therapeutics Co., Ltd

Based in Chengdu, China, and established in 2016, Sichuan Cunde Therapeutics Co. , Ltd is a biopharmaceutical companies' company that focuses on diagnosis and treatment research services and product development of major disease, such as tumors and liver cirrhosis. The company was incubated by Chongqing Lummy Pharmaceutical Co. , Ltd.

The company has received the national 13th Five-Year Major New Drug Innovation and Technology Major Special support. Its products obtained the first bath of products supported by the Sichuan provincial Drug Administration in the early intervention implementation plan for new drug R&D. In September 2025, Sichuan Cunde Therapeutics Co. , Ltd raised Series A funding from new investor Dongna Investment.

The company operates the development, transformation, and application of new cell therapy technologies in the field of human diseases, such as malignant tumors and liver cirrhosis. It self-developed Cunde technology platform that is a personalized tumor vaccine development platform. According to the patient's personalized tumor neoantigens, autologous dendritic cells are used as carriers to improve the recognition of tumors cells by the human immune system and improve the immunogenicity of tumor cells to kill tumor cells, inhibit tumor growth, and reduce tumor recurrence. Specific product includes therapeutic tumor vaccine, therapeutic tumor vaccine, and individualized anti-liver fibrosis macrophage injection.

Revenue is generated through hardware sales, custom integration projects, and long-term supply agreements with industrial clients. Additional income may come from embedded software support and technical services.